July 23, 2019

For the Record: Grassley on Prescription Drug Pricing

For the Record: Grassley
on Prescription Drug Pricing

 

Senate Finance Committee
Chairman Chuck Grassley (R-Iowa) has worked for greater access and
affordability of prescription drugs throughout his time in the Senate. His
efforts have included aggressive oversight and smart, bipartisan legislation.

 

Whether advocating for
increased competition on the prescription drug market, calling for greater
transparency across all sectors of the health care system or stopping drug
companies from gaming the system for their own financial gain, Grassley has been
a constant proponent of finding solutions to lower drug costs for American
patients and taxpayers.

 

Recent
Oversight

 

Insulin Price
Investigation

The Centers for Disease
Control and Prevention (CDC) estimates that more than 30 million Americans have
diabetes. On January 29, 2019, the Finance Committee, led by Chairman Grassley,
held a hearing on drug pricing.
One witness, Kathy Sego, 
testified that her son, worried
about the financial burden that the monthly $1,700 cost of insulin was having
on his parents, began rationing treatment at the sacrifice of his health.

 

·     
February 22, 2019 – Grassley and Ranking
Member Ron Wyden (D-Ore.) sent letters to Eli Lilly, Novo Nordisk
and Sanofi, the three largest insulin manufacturers in the United States to
investigate insulin prices.

·     
April 2, 2019 – Grassley and Wyden sent letters to leading pharmacy benefit managers (PBMs)
regarding their role as middlemen in the skyrocketing cost of insulin.

·     
April 3, 2019 – Cigna (Express Scripts) announced it
would cap out-of-pocket costs for insulin prescriptions for some patients.

 

Direct-to-Consumer
Advertising

The average American sees nine DTC prescription
drug ads each day. Studies show that patients are more likely to ask their
doctor for a specific brand-name medication, and doctors are more likely to
prescribe one, when they have been marketed directly with drug advertisements.
Chairman Grassley and Sen. Dick Durbin (D-Ill.)
introduced legislation to require price disclosures
in DTC advertisements.

 

·     
November 16, 2018 – Grassley and Durbin
wrote a letter to HHS and called for implementation of proposed regulations
requiring pharmaceutical companies to list prices of their prescription drugs
in direct-to-consumer (DTC) advertisements.

·     
May 8, 2019 – HHS announced the issuance of final
regulations requiring pharmaceutical companies to companies disclose
prescription drug prices in TV ads.

·     
May 13, 2019 – Grassley and Durbin introduce
legislation to codify HHS regulation.

·     
July 11, 2019 – Grassley and Durbin vow to keep pushing
for transparency after a federal judge rules DTC ads do not have to include
list prices of prescription drugs.

 

Competition

Chairman
Grassley has long supported efforts to combat anti-competitive tactics in the
pharmaceutical market. Along with Sen. Amy Klobuchar (D-Minn.), Grassley
introduced the Preserve
Access to Affordable Generics Act
. The legislation limits “pay for delay”
deals where brand-name and generic drug manufacturers use anti-competitive
pay-off agreements to delay cheaper alternatives from reaching consumers.

 

Grassley and
Klobuchar also introduced
the Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of
New Generics (STOP STALLING) Act. This legislation enhances the FTC’s ability
to bring cases against entities that abuse the FDA’s citizen petition process
by filing sham petitions to stop or delay the approval of generic competitors.

 

Grassley and
Leahy
introduced the Creating
and Restoring Equal Access to Equivalent Samples 
(CREATES) Act.
The legislation addresses abuses and delay tactics by brand-name companies that
prevent generic companies from performing the necessary testing and
distribution necessary for U.S. Food and Drug Administration (FDA) approval.
The Congressional Budget
Office (CBO) estimated that the bill would result in almost $4 billion in
savings.

 

·     
June 22, 2018 – Grassley and Klobuchar sent a letter to
the FTC urging them to examine whether makers of biologic medicines are using
strategies like “pay-for-delay” to hinder or delay biosimilars from entering
the market.

·     
August
14, 2018
–
Grassley sent a letter to the Justice Department urging it to conduct a
vigorous review of the proposed mergers of Cigna Corp. with Express Scripts
Holding Co., and CVS Health Corp. with Aetna, Inc., each of which play
significant roles in the price of prescription drugs for U.S. consumers.

·     
August
17, 2018
–
Grassley sent a letter to the FTC urging it to conduct an assessment of recent
and ongoing consolidation in the pharmaceutical supply chain and its potential
impact on prescription drug prices for U.S. consumers.

·     
October
10, 2018
–
Grassley sent a letter to the FTC urging it to conduct an assessment of
potentially anticompetitive contracting practices between insurers and hospital
systems in the U.S. deliberately designed to prevent consumers’ access to
quality, lower cost care.

·     
November 8, 2018 – Grassley and Klobuchar
sent a letter to President Trump urging him to support legislation to limit
“pay-for-delay” pharmaceutical settlements as part of the Administration’s
effort to bring down the skyrocketing price of prescription drugs.

 

Drug Importation

Chairman Grassley has
been a consistent supporter of importing prescription drugs from Canada. The
first reimportation vote in the U.S. Senate occurred in July 2000 on an
amendment offered by former Sen. Jim Jeffords (I-Vt.), which Grassley
supported. Grassley voted a second time for reimportation of prescription drugs
from Canada in July 2002 on an amendment offered by former Sen. Byron Dorgan
(D-N.D.). Grassley voted for another Dorgan amendment when it was offered in
June 2003. In 2004 and 2005, Grassley introduced
the Reliable Entry for Medicines at
Everyday Discounts through Importation with Effective Safeguards
 (REMEDIES)
Act
. The bill makes it legal for U.S. consumers to buy safe prescription
drugs from Canada.

 

·     
November
23, 2015
– Grassley and McCain sent a letter to then-HHS Secretary Sylvia
Matthews Burwell to urge her to increase drug importation from Canada.

·      February
14, 2017
– Grassley, McCain and Klobuchar sent a letter to then
HHS-Secretary Tom Price urging him to him to fast track the importation of
prescription drugs from Canada.

·      July
19, 2018
– HHS announces it would create a task force to explore
prescription drug importation as a way to reduce U.S. drug prices.

 

Medicaid Drug Rebate
Program

Grassley is a longtime
advocate for lower prescription drug prices and has been a vocal critic of
EpiPen’s exorbitantly high cost. Iowans regularly contact Grassley by phone,
email and at his annual 99 county meetings about the difficulties they faced
paying for the anti-allergy EpiPen device. After conducting oversight of the
issue in 2016 and 2017, Grassley learned that Mylan, EpiPen’s distributor,
classified its popular anti-allergy medicine as a generic instead of as a brand
name product in the Medicaid Drug Rebate Program (MDRP). That incorrect
classification allowed Mylan to pay smaller rebates to States and government
programs, such as the MDRP. Grassley’s investigation also found that HHS and
the HHS Inspector General did not have adequate authorities to properly oversee
the MDRP and ensure drugs were properly classified. The costly practices were
confirmed by the HHS Inspector General when it found – at Grassley’s request –
that taxpayers may have
overpaid for the EpiPen by as much as $1.27 billion over 10 years. The Inspector General
also found that additional drugs could be misclassified.  

 

·     
August 22, 2016 – Grassley sent a letter
to Mylan Chief Executive Officer Heather Bresch asking her to explain a steep
price increase for EpiPens.

·     
August 24, 2016 – Grassley sent a letter
with four other senators to then-FDA Commissioner Robert Calliff asking about
FDA’s approval process and other steps for alternatives to EpiPen.

·     
August 25, 2016 – Grassley reiterated
his expectation for answers from Mylan after an announcement the company would
expand its patient assistance programs.

·     
August 29, 2016 – Mylan announces it
will make a generic version of EpiPen available.

·     
August 31, 2016 – Grassley, along with
two other senators, sent a letter to then-Acting CMS Administrator Andrew
Slavitt asking for information on the effect of Mylan’s price increases on the
government’s prescription drug costs.

·     
September 6, 2016 – Grassley sent a letter
to Iowa Attorney General Tom Miller asking him to review whether Iowa taxpayers
overpaid for EpiPens under Medicaid.

·     
September 9, 2016 – Grassley receives
unsatisfactory response from Mylan to his August 22, 2016 letter.

·     
September 20, 2016 – Grassley, along with
fellow Senate Finance Committee Republicans, sent a letter to HHS IG urging for
an exam of CMS’ oversight of the MDRP.

·     
September 28, 2016 – Grassley, Klobuchar
and Sen. Richard Blumenthal (D-Conn.) asked the Justice Department (DOJ) to
consider investigating whether Mylan violated the law by misclassifying EpiPen.

·     
October 3, 2016 – Grassley sent a letter
to Slavitt requesting records related to EpiPen’s classification for purposes
of the MDRP.

·     
October 3, 2016 – Grassley sent a letter
to Bresch asking again for her to explain the steep price increase for EpiPens.

·     
October 6, 2016 – Grassley releases
findings on EpiPen costs to taxpayers.

·     
October 7, 2016 – Mylan settles case
with DOJ regarding overcharging taxpayers for EpiPen.

·     
October 11, 2016 – Grassley sent a letter
to Attorney General Loretta Lynch seeking details about DOJ’s settlement with
Mylan.

·     
November 1, 2016 – Grassley sent letters
to the Departments of Defense (DoD) and Veterans Affairs (VA) seeking
information on agency spending for EpiPens.

·     
November 7, 2016 – Grassley, Blumenthal
and Klobuchar call on Mylan to reimburse DoD for overpayments for EpiPens.

·     
November 7, 2016 – Grassley and Sen.
Patrick Leahy (D-Vt.) sent a letter to Federal Trade Commission (FTC)
Chairwoman Edith Ramirez asking for a review of Mylan’s business practices with
respect to EpiPen.

·     
November 8, 2016 – Grassley sent a letter
to the HHS IG asking for its records over the identification in 2009 of
EpiPen’s misclassification that led to overcharging taxpayers.

·     
November 21, 2016 – Grassley sent a letter
to the Securities and Exchange Commission (SEC) asking for information on
whether the commission was looking into Mylan’s potential misleading of
investors regarding its settlement with DOJ.

·     
December 6, 2016 – HHS confirmed it would
conduct three new reviews of the MDRP at the request of Grassley and fellow
senators.

·     
December 12, 2016 – Grassley sent a letter
to then-President-elect Trump urging appropriate classification under the MDRP.

·     
January 4, 2017 – Grassley sent a letter
to Slavitt seeking information on if the Obama administration knew certain
drugs were misclassified under MDRP, oversight efforts of the program and what
steps the Administration was taking to fix the problem.

·     
January 5, 2017 – Grassley sent a letter
to CMS asking if it sought to recoup tax dollars overpaid for EpiPens from
Mylan.

·     
January 25, 2017 – After receiving no
response, Grassley sent a follow-up letter to CMS asking if it sought to recoup
tax dollars overpaid for EpiPens from Mylan.

·     
March 8, 2017 – Grassley sent a letter to Mylan
competitor Kaleo Pharmaceuticals to explain its pricing for Auvi-Q.

·     
June 15, 2017 – The Trump administration announces it
is working on an executive order to address high prescription drug prices.

·     
August 17, 2017 – Mylan agrees to pay
$465 million to resolve False Claims Act Liability after underpaying Medicaid
rebates on EpiPen.

·     
October 31, 2017 – Grassley sent a letter
to Miller asking for more details regarding Iowa’s receipt of $1.5 million as
part of the DOJ, Mylan settlement over EpiPen.

·     
August 16, 2016 – FDA approves the first
generic version of the EpiPen.

 

Recent
Legislation

 

Sponsored

·      Prescription Pricing for the People Act of 2019 

o  
Requires
the FTC to study the role and recent merger activity of pharmacy benefit
managers and other supply chain intermediaries, as well as possible
anticompetitive behavior, and to provide policy recommendations to Congress to
promote transparency and competition.

·      
Safe
and Affordable Drugs from Canada Act of 2019
 

o  
Permits the importation of
prescription drugs from approved pharmacies in Canada. This legislation intends
to provide safe and less expensive prescription drugs for U.S. consumers.

·      Ensuring the Value of the 340B Program Act  

o  
Increases
transparency in a targeted way into the 340B program by
requiring
participating hospitals to report the total
acquisition costs for drugs collected through the 340B program, as well as
revenues received from all third party payers for those same drugs.

·       Advancing Care for Exceptional Kids Act

o  
Allows
health care providers to coordinate care, lower costs, and improve quality
outcomes for children with complex medical conditions on Medicaid who require
specialized care.

·     
Reliable Entry for Medicines at Everyday Discounts through
Importation with Effective Safeguards (REMEDIES) Act

o   Makes it legal for U.S.
consumers to buy safe prescription drugs from Canada.

 

Co-Sponsored

·      Stop
Significant and Time-Wasting Abuse Limiting Legitimate
Innovation of New Generics (Stop STALLING) Act

o   Curbs sham petitions by
drugmakers to delay FDA approval of lower-cost alternatives. 

·      Creating and Restoring Equal Access to Equivalent
Samples (CREATES) Act
 

o   Deters pharmaceutical
companies from blocking cheaper generic alternatives from entering the
marketplace by preventing access to drug samples needed for testing. 

·     
Short
on Competition Act

o  
Allows
HHS to grant expedited reviews and inspections, and temporary importation when
there is, or is likely to be, a drug shortage or when there are fewer than five
competitors in a market for drugs that have been approved for at least 10
years.

·      
Preserve Access to Affordable Generics and Biosimilars Act  

o  
Stops
anti-competitive pay-off agreements that keep more affordable generic and
biosimilar equivalents off the market and makes sure consumers have access to
the lower cost pharmaceuticals they need.

·     
Patient Right to Know Drug Prices Act

o  
Eliminates pharmacy “gag clauses” that prevent pharmacists
from informing customers when they could get their medication cheaper by paying
out-of-pocket.

·      Right
Rebate Act of 2019

o  
Provides
HHS with additional authorities to monitor drug manufacturers who participate
in MDRP and impose reporting and transparency requirements on the government to
show how the additional authorities have been used. Also allows the secretary
to require drug manufacturers to reclassify their drugs and impose civil
monetary penalties when drugs are knowingly misclassified.

·     
Durbin-Grassley
DTC Advertising Amendment
 

o  
Requires
pharmaceutical companies to list prices of their prescription drugs in DTC
advertisements.

-30-

Print 
Email 
Share 
Share